ÂÜÀòÂÒÂ×

Jay Park is the current Chief Operating Officer at TeraImmune. Prior to this, they worked as a postdoc at NIH from March 2014 to October 2018, where they researched the role of mitochondrial p53 in tumor development, the effect of p53 mutations on cancer cell metabolism, and ways to prevent tumor development through pharmacological inhibition of mitochondrial respiration. Before their time at NIH, Jay was a research professor at Chungnam National University from March 2011 to February 2014, working in the Department of Biochemistry in the College of Medicine. Jay's research has also focused on the anti-necrotic mechanisms of NecroX-7 in acetaminophen-induced acute liver injury in C57Bl/6 mice, the regulation of HIF1a stability via deacetylation by SIRT2, and the inhibition of LPS-induced HMGB1 release by anti-oxidants in macrophage.

Jay Park received their Doctor of Philosophy in Biochemistry from Chungnam National University. Jay also holds a Master of Science in Biochemistry from Chungnam National University and a Bachelor of Science in Biochemistry from Chungnam National University. Jay is certified by the FAES, NIH in Advanced Studies in Technology Transfer.

Their manager is Yong Chan Kim, Chief Executive Officer. Some of their coworkers include Keith Bryant - Chief Business Officer.